XML 60 R50.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaborative Agreements (Details) - Collaborative Arrangement, Product [Member]
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2015
USD ($)
Aug. 07, 2015
USD ($)
product
Feb. 28, 2017
USD ($)
Sep. 30, 2015
USD ($)
Apr. 30, 2015
USD ($)
Sep. 30, 2013
USD ($)
Sep. 30, 2017
USD ($)
Jun. 30, 2017
USD ($)
Sep. 30, 2016
USD ($)
Sep. 30, 2017
USD ($)
Sep. 30, 2016
USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Upfront payment received           $ 10,000          
INO-3112 [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Revenue recognized $ 15,000                    
License To Research Collaboration Products [Member] | Nonsoftware License Arrangement [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Deferred revenue, additions 12,500 $ 12,500                  
INO 5150 [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Revenue recognized           8,400          
Option Right [Member] | Nonsoftware License Arrangement [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Deferred revenue, additions           1,500          
Joint Steering Committee Obligation [Member] | Nonsoftware License Arrangement [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Deferred revenue, additions           $ 155          
MedImmune [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Upfront payment received $ 27,500     $ 27,500              
Anticipated development and regulatory event based payment receivable milestones   $ 700,000                  
Number of additional products to be developed | product   2                  
Revenue under collaborative research and development arrangements             $ 344   $ 581 $ 14,900 $ 1,300
Accounts receivable             501     501  
Roche [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Full payment     $ 8,500                
Clawback portion               $ 2,100      
Hoffman-La Roche [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Previously deferred revenue recognized             0   1,700 6,100 4,700
Defense Advanced Research Projects Agency (DARPA) [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Accounts receivable             5,700     5,700  
Previously deferred revenue recognized             1,400   $ 9,400 9,100 $ 17,600
Term         2 years            
Base award         $ 19,600            
Option award         24,600            
Second option award         $ 11,100            
Deferred revenue             $ 245     $ 245